Pulmonary emphysema
Therapeutic area
Pulmonology
Rare disease
No
- Definition
- A subcategory of chronic obstructive pulmonary disease (COPD). It occurs in people who smoke and suffer from chronic bronchitis. It is characterized by inflation of the alveoli, alveolar wall damage, and reduction in the number of alveoli, resulting in difficulty breathing.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Pulmonary emphysema
- Therapeutic area
- Pulmonology
- pulmonary emphysema
- emphysema
- emphysema, pulmonary
- All therapeutic areas
- Pulmonology
- Severity
- Moderate
- MONDO ID
- MONDO:0004849
- Parent condition
- MONDO:0005002
Related records
Broader conditions (10)
- Chronic obstructive pulmonary disease
- Disease
- Disease by body system or component
- Human disease
- Lower respiratory tract disorder
- Lung disorder
- Obstructive lung disease
- Respiratory system disorder
- Tracheal disorder
- Upper respiratory tract disorder
Narrower conditions (5)
- Compensatory emphysema
- Congenital lobar emphysema
- Emphysema, hereditary pulmonary
- Hyperlucent lung
- Interstitial emphysema
Trials (410)
- 28-day Repeat Dose Study of GSK573719
- 4D Medical X-ray Velocimetry for Bronchoscopic Lung Volume Reduction Targeting
- 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease
- A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
- A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
- A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- A Clinical Evaluation of Baofeikang Granule in Combined Pulmonary Fibrosis and Emphysema Treatment
- A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema
- A Dose Ranging Study of the Aeris Polymeric Lung Volume Reduction (PLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema
- A Home-based Intervention to Promote Mindful Breathing Awareness Through Pursed-lip Breathing Training for COPD Patients
- A Multi Center Study Testing a New Implant for Adults With Severe Emphysema
- A Multi-center RCT to Evaluate Subsegmental BTVA Treatment for Severe Emphysema
- A Multicenter, Prospective Trial of the IAB in Adults Suffering From COPD/Emphysema
- A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
- A Phase I Study of iPS Cell Generation From Patients With COPD
- A Pilot Study to Assess Treatment of Patients With Homogeneous Emphysema Using Sequential Segmental Bronchoscopic Thermal Vapor Ablation (NEXT STEP)
- A Pilot Study to Evaluate the ROX Anastomotic Coupler System in Patients With Chronic Obstructive Pulmonary Disease
- A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe Emphysema
- A Randomized Controlled Trial of InterVapor® in France - The TARGET Trial
- A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Approved drugs (12)
- Aclidinium bromide
- Arformoterol tartrate
- Budesonide
- Fluticasone propionate
- Formoterol fumarate
- Indacaterol maleate
- Ipratropium bromide
- Olodaterol hydrochloride
- Salmeterol xinafoate
- Tiotropium bromide
- Umeclidinium bromide
- Vilanterol trifenatate
Drugs in development (14)
- Arformoterol Phase 3
- Basiliximab Phase 3
- Belimumab Phase 2
- Cilomilast Phase 3
- Doxycycline Phase 2
- Formoterol Phase 3
- Ibuprofen Phase 2
- Isotretinoin Phase 2
- Palovarotene Phase 2
- Retinoic acid receptor .GAMMA. Phase 2
- Salmeterol Phase 3
- Sildenafil citrate Phase 2
- Sodium chloride Phase 2
- Tretinoin Phase 2
Other linked drugs (3)
- .ALPHA.1-proteinase inhibitor human
- Fluticasone furoate
- Glycopyrronium bromide